Meeting
Abstract Number: 120
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality, and cost with the greatest proportion incurred treating acute exacerbations of COPD (AECOPD). While guidelines recommend oral steroids for the treatment of AECOPD, parental corticosteroids are still used in the inpatient setting; such use is associated with high costs and adverse effects. The […]
Abstract Number: 140
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: The US healthcare system is under increasing pressure to improve value and affordability. Acute care is responsible for a large proportion of overall health costs, but the complexities and pace in this environment have left an evidence gap in value-based care transformation. Novel improvement and evaluation strategies are thus needed more than ever to […]
Abstract Number: 216
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: COPD exacerbations are among the leading causes of hospital readmissions. According to the COPD Foundation, in 2013, 22% patients admitted for COPD exacerbation required readmission within 30 days of discharge. This represents a significant burden in terms of morbidity for these patients and increased cost to the healthcare system. The COPD readmission rate during […]
Abstract Number: 339
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Currently, once-daily nebulized bronchodilator therapy is unavailable for patients with chronic obstructive pulmonary disease (COPD). Prior studies demonstrated that once-daily revefenacin (REV) doses of 88 and 175 µg produced significant bronchodilation in COPD patients. We report the pooled results of two replicate phase 3 efficacy trials. Methods: In these double-blind, placebo-controlled, parallel-group, 12-week trials […]